The most overlooked corner of AI could be biology. Capital spent the last three years chasing compute and robotics while AI for biology lagged behind. The 2021 biotech collapse hit longevity especially hard, and the sector never drew the enthusiasm the rest of AI did. That skepticism lingered even as record investment flowed into the space around it. The technology has started to change that. The methods that cracked protein folding are now reaching cellular problems that were previously out of reach. Companies like Altos Labs, NewLimit, and Life Biosciences have drawn major funding. The FDA doesn't recognize aging as a disease, so companies target specific age-related illnesses first. The real ambition is to treat aging itself. 10,000 Americans turn 65 every day, and Social Security's reserves are projected to deplete in the early 2030s. GLP-1s could be the start of a much larger longevity wave. (Original content provided by @PonderingDurian at Delphi Ventures)